A large-scale neuroimaging study published in early 2025 has provided some of the clearest evidence yet that heavy cannabis use is associated with reduced brain activity during working-memory tasks, raising fresh concerns about the cognitive consequences of legalization-era consumption patterns. The research, led by scientists at the University of Colorado Anschutz Medical Campus and published in JAMA Network Open, scanned more than 1,000 young adults and found that those with a history of heavy cannabis use showed significantly diminished activation in brain regions tied to attention, decision-making and memory.
The findings arrive at a moment when cannabis use among adults in the United States has reached historic highs. According to data tracked by the National Institute on Drug Abuse, daily or near-daily marijuana use now exceeds daily alcohol consumption for the first time on record, a shift driven by widespread state-level legalization, expanded medical access, and the proliferation of high-potency products. Researchers have long suspected that habitual use could alter neural function, but most prior studies relied on small samples or self-reported behavioral data without direct imaging evidence.
What the Researchers Found
The team, led by Dr. Joshua Gowin, used functional magnetic resonance imaging (fMRI) to measure brain activity in 1,003 young adults aged 22 to 36 drawn from the Human Connectome Project. Participants performed seven cognitive tasks while inside the scanner, covering domains including working memory, reward processing, emotional regulation, language, and motor function. The most striking finding emerged during the working-memory task: heavy lifetime cannabis users — those who had used the drug more than 1,000 times — showed measurably lower activation in regions including the dorsolateral prefrontal cortex and the anterior insula, both of which are central to executive function.
Importantly, the effect was not limited to people who had used cannabis in the hours before the scan. Even after controlling for recent intake, the lifetime-use signal persisted, suggesting cumulative rather than purely acute effects. “We can predict who’s going to have less brain activity based on their cannabis use,” Gowin told reporters following publication, cautioning that while the imaging differences were statistically robust, the long-term clinical implications remain to be mapped.
Context: A Changing Regulatory and Scientific Landscape
The new evidence lands amid a broader policy reassessment. The U.S. Drug Enforcement Administration has been weighing the rescheduling of cannabis from Schedule I to Schedule III, a move that would acknowledge accepted medical uses while loosening research barriers. Public-health agencies, including the Centers for Disease Control and Prevention, have warned that today’s cannabis products often contain THC concentrations several times higher than those of a generation ago, complicating any direct comparison with older epidemiological literature.
Neuroscientists outside the study group have urged measured interpretation. Reduced fMRI activation does not automatically translate into impaired performance, and the participants in this cohort largely completed the tasks at comparable accuracy levels. However, prior work — including longitudinal data summarized in journals such as The Lancet Psychiatry — has linked heavy adolescent and young-adult cannabis exposure to subtle declines in IQ, attention, and educational attainment over time.
Why It Matters
For clinicians, the study reinforces the case for screening cognitive symptoms in patients reporting frequent use, particularly those who began consuming during adolescence when prefrontal circuitry is still maturing. For policymakers, it adds neurobiological weight to ongoing debates about THC potency caps, age restrictions, and public-health messaging in newly legal markets. And for everyday users, it offers a concrete neural correlate to a question many have asked: does heavy use leave a footprint on the brain? On the evidence of this study, it appears to.
What to Watch Next
Gowin’s group has signaled plans to follow participants longitudinally to determine whether the imaging differences predict real-world cognitive outcomes such as job performance, academic achievement, or risk of psychiatric conditions like cannabis use disorder. Parallel work using newer scanning methods and high-potency exposure cohorts is underway in Canada and Europe. Expect the next 12 to 24 months to bring sharper answers on dose-response thresholds — and likely renewed pressure on regulators to translate neuroscience into product standards.
For more reporting on neuroscience, brain health, and the science behind everyday behavior, visit science.wide-ranging.com for related articles and ongoing coverage.
